Abstracts Archive - Page 272 of 2607 - ACR Meeting Abstracts

Abstract Number: 0658 • ACR Convergence 2024
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Richard Furie¹, Amit Saxena², Samir Parikh³, Richard Leff⁴, Lucas Bohnett⁵, Kathryn Ray⁶, Brian Tuch⁴, Janet Anderl⁴, Jennifer Whang⁴ and Kiruthi Palaniswamy⁷, ¹Northwell Health, Manhasset, NY, ²NYU School of Medicine, New York, NY, ³Ohio State University, Columbus, OH, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, El Cajon, ⁶Kezar Life Sciences, Mill Valley, CA, ⁷Kezar Life Sciences, Inc, South San Francisco, CA
Background/Purpose: Zetomipzomib is a selective inhibitor of the immunoproteasome with anti-inflammatory and immunomodulatory potential without evidence of immunosuppression to date. The MISSION study (NCT03393013), a…
Abstract Number: 0624 • ACR Convergence 2024
Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis
Dong-Jin Park¹, Hyemin Jeong², Sung-Eun Choi³, Ji-Hyoun Kang² and Shin-Seok Lee⁴, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Chonnam National University Hospital, Gwangju, South Korea, ³Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Conflicting studies have reported varying associations between tubulointerstitial inflammation (TII), tubulointerstitial damage (TID), and the long-term outcomes of lupus nephritis (LN), due to analyzing…
Abstract Number: 0639 • ACR Convergence 2024
Delayed Diagnosis in Systemic Lupus Erythematosus
Romina Nieto¹, Lucia Hernandez², Nidia Noemí Merás³, Bordón Florencia Juliana⁴, Cintia Otaduy⁵, Lucila Garcia⁶, Rosa Serrano Morales⁷, Nicolás Pérez⁸, Micaela A. Cosatti⁹, Ana Carolina Montandon¹⁰, Gustavo Flores Chapacais¹¹, Laissa C. Alves Alvino¹², Emily Figuereido Neves¹³, Eloisa Bonfa¹⁴, Alexis Bondi Peralta¹⁵, Loreto Massardo¹⁶, Andrés Cadena Bonfanti¹⁷, Andrés Hormaza¹⁸, José Martínez¹⁹, Olga Lidia Vera Lastra²⁰, Hilda Fragoso-Loyo²¹, ⁠Yaneli Juárez-Vicuña²², Diana Fernandez²³, Patricia Langjarth²⁴, Maria Teresa Martinez de Filartiga²⁵, Manuel Ugarte-Gil²⁶, Carlos Alejandro Loayza Flores²⁷, Teresandris Polanco²⁸, Maria Belen Lecumberri²⁹, Álvaro Danza³⁰, Carlos Enrique Toro-Gutierrez³¹, Urbano Sbarigia³², Ashley Orillion³³, Federico Zazzetti³⁴, Graciela Alarcon³⁵, Bernardo Pons-Estel² and Guillermo Pons-Estel³⁶, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ³Hospital Italiano de Córdoba, Cordoba, Argentina, ⁴Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁵Hospital Córdoba, Cordoba, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, ⁷Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁸Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁹CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, ¹⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ¹¹Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹³Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Hospital del Salvador, Santiago, Chile, ¹⁶Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, ¹⁷Universidad Simon Bolivar, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²²Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, ²³Member of GLADEL, Rosario, Argentina, ²⁴Hospital de Clínicas I, Asunción, Paraguay, ²⁵Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, ²⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ²⁷Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁸Hospital Docente Padre Billini, Santo Domingo, Dominica, ²⁹Hospital Señor del Milagro, Salta, Argentina, ³⁰Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁵The University of Alabama at Birmingham, Oakland, CA, ³⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…
Abstract Number: 0530 • ACR Convergence 2024
Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein², Marike van der Leeden², Franktien Turkstra², Jos Twisk³, Maarten Boers³, Henriët van Middendorp⁴, Peter Weijs⁵ and Dirkjan van Schaardenburg⁶, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁴Leiden University, Leiden, Netherlands, ⁵Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle intervention, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 0600 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Laure Gossec¹, Dafna Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Jérémy Lambert⁷ and Ana-Maria Orbai⁸, ¹Sorbonne Université, Paris, France, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁴Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Colombes, France, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…
Abstract Number: 0526 • ACR Convergence 2024
Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
Narendra Maharaj¹, Dharma rao Uppada², Naveen Reddy MAREDDY¹, Pramod Reddy Pundra¹, Anastas Batalov³, Delina Ivanova⁴, nedyalka staykova⁵, Asta Baranauskaite⁶ and Laila Hassan⁷, ¹Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, ²Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, ³Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, ⁴Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, ⁵Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, ⁶Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, ⁷11914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX
Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
Abstract Number: 0665 • ACR Convergence 2024
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
Nicolai Leuchten¹, Ioannis Parodis², Ralph Brinks³ and Martin Aringer¹, ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ³University Witten/Herdecke, Witten, Germany
Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…
Abstract Number: 0654 • ACR Convergence 2024
Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus
Miral Gharib¹, Georgios Baloglu Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Alemadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Weill Cornell Medicine , Qatar, doha, ³Weill Cornell Medicine , Qatar, doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms associated with poor outcomes. Small fiber neuropathy can cause intolerable…
Abstract Number: 0410 • ACR Convergence 2024
Efficacy of Modified Dosing/interval Timing of Adalimumab in Patients Affected by Chronic Non Infectious Uveitis: A Retrospective Monocentric Study
Melissa Lerman¹, Devlin Eckardt¹ and Sabino Germinario², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Università degli studi di Milano, Milan, Italy
Background/Purpose: Non-infectious uveitis (NIU), inflammation of the eye, can occur in isolation, as in idiopathic uveitis (29% of all pediatric diagnosis), but may also be…
Abstract Number: 0541 • ACR Convergence 2024
Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Clementina López Medina¹, Anna Molto², Dafne Capelusnik³, Philippe Carron⁴, Casper Webers⁵, Filip Van den Bosch⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴UZ Gent, Gent, Belgium, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Understanding the best-performing disease activity measure and response criterion in peripheral spondyloarthritis (pSpA) is crucial for the development of future meaningful clinical studies. The…
Abstract Number: 0611 • ACR Convergence 2024
Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
Arthur Mageau¹, Marie-Paule Chauveheid², Chrystelle Francois², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…
Abstract Number: 0414 • ACR Convergence 2024
Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis
Andrew Grim¹, Yongdong (Dan) Zhao², Christine Wang¹, Erin Janssen³, Jessica Turnier⁴, Anastasia Hyrhorczuk¹ and Nadine Saad¹, ¹University of Michigan, Ann Arbor, MI, ²University of Washington, Redmond, WA, ³CS Mott Children's Hospital, Ann Arbor, MI, ⁴University of Michigan, Saline, MI
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder. Some patients with CNO may present acutely and be misdiagnosed as infectious osteomyelitis (IO).…
Abstract Number: 0647 • ACR Convergence 2024
Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus
Pankti Mehta¹, Fadi Kharouf², Qixuan Li³, Laura Patricia Whittall Garcia³, Dafna Gladman⁴ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Pericarditis is an important feature in the classification criteria and disease activity assessments in Systemic Lupus Erythematosus (SLE). We aimed to study the prevalence,…
Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 0460 • ACR Convergence 2024
Cartilage Damage or (sub)luxation of Finger Joints: Impact on Physical Function in Patients with Rheumatoid Arthritis
Takehisa Ogura¹, Yasuto Minegishi², Chihiro Imaizumi¹, Reina Maezawa¹, Takaharu Katagiri¹ and Hideto Kameda¹, ¹Toho university, Tokyo, Japan, ²Toho University, Tokyo
Background/Purpose: It has been reported that radiographic joint space narrowing (JSN) score affects the health assessment questionnaire-disability index (HAQ-DI) score in rheumatoid arthritis (RA) patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].